EQL Pharma AB (OSTO:EQL) ROCE %: 3.20% (As of Mar. 2026)


OSTO:EQL EQL Pharma AB OSTO:EQL
42 GF Score
Price kr23.15
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB ROCE %?

EQL Pharma AB OSTO:EQL -2.32% 42 ROCE % is 3.20% as of Mar. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. EQL Pharma AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 3.20%.

EQL Pharma AB  (OSTO:EQL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

EQL Pharma AB ROCE % Related Terms

EQL Pharma AB ROCE % Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB ROCE % Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.36 26.88 18.06 16.85 7.93

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.97 13.77 2.33 12.30 3.20
OSTO:EQL
42GF Score
EQL Pharma AB OSTO:EQL
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB ROCE % Calculation

EQL Pharma AB's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=48.692/( ( (808.823 - 221.018) + (850.887 - 210.231) )/ 2 )
=48.692/( (587.805+640.656)/ 2 )
=48.692/614.2305
=7.93 %

EQL Pharma AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=20.464/( ( (813.537 - 174.366) + (850.887 - 210.231) )/ 2 )
=20.464/( ( 639.171 + 640.656 )/ 2 )
=20.464/639.9135
=3.20 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 3.20% mean?
EQL Pharma AB (OSTO:EQL) has a ROCE % of 3.20% as of Mar. 2026.
Is EQL Pharma AB's ROCE % too high?
EQL Pharma AB's current ROCE % is 3.20%. The Drug Manufacturers industry median ROCE % is 7.03. EQL Pharma AB's value of 3.20% is 54.5% below this industry median. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's ROCE % compare to ZTS and UTHR?
EQL Pharma AB's ROCE % of 3.20% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. EQL Pharma AB's value of 3.20% is 54.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current ROCE % of 3.20% is 54.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current ROCE % is 3.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current ROCE % of 3.20%. The current ROCE % is 3.20% and 54.5% below the Drug Manufacturers industry median of 7.03. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current ROCE % is 3.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges 7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score

Get the complete analysis for OSTO:EQL

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.15
Price